<DOC>
	<DOCNO>NCT02738632</DOCNO>
	<brief_summary>Randomized , Double-Blind , Multi-Center , Phase 3 Trial Evaluate Efficacy Safety Telmisartan/Amlodipine/Hydrochlorothiazide Combination Comparison Telmisartan/Amlodipine Combination Essential Hypertension Patients Controlled Telmisartan/Amlodipine Combination</brief_summary>
	<brief_title>Efficacy Safety TAH Combination Comparison With Telmisartan/Amlodipine Combination Essential Hypertension Patients</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>1 . 19 year old Koreans live Korea 2 . Patients uncontrolled essential hypertension screening time ( Visit 1 ) Naïve : 160 mmHg ≤ sitSBP &lt; 200 mmHg Use antihypertensive drugs:140 mmHg ≤ sitSBP &lt; 200 mmHg 3 . Patients uncontrolled hypertension Telmisartan/Amlodipine 40/5mg treatment 6 week randomization ( Visit 2 ) 140 mmHg ≤ sitSBP &lt; 200 mmHg 4 . Patients agree participate trial 1 . Test result show follow value screen time ( Visit 1 ) The change mean sitSBP ≥ 20 mmHg sitDBP ≥ 10 mmHg target arm 1st 2nd measurement screening time ( Visit 1 ) , time randomization ( Visit 2 ) : sitDBP ≥ 120 mmHg 2 . Patients secondary blood pressure suspect secondary blood pressure ( example , aortic coarctation , primary aldosteronism , renal artery stenosis , pheochromocytoma ) 3 . Patients congestive heart failure ( NYHA class III~IV ) Patients unstable angina myocardial infarction valvular heart disease within 6 month prior study entry Patients severe ventricular tachycardia , atrial fibrillation , atrial flutter clinically significant arrhythmia 4 . Patients history cerebrovascular disease cerebral infarction , cerebral hemorrhage within 6 month prior study entry 5 . Type I Diabets Mellitus Type II Diabetes Mellitus HbA1c &gt; 9 % 6 . Patients history severe malignant retinopathy within 6 month prior study entry 7 . Patients suspect Renal dysfunction may affect absorption , distribution , metabolism excretion ( Serum Creatinine : &gt; 2mg/dL ) , gastrointestinal , haematological , liver disease ( AST ALT &gt; 2.5 time upper limit normal range ) 8 . Patients administer antihypertensive drug clinical trial medication ( Diuretics , βblockers , ACE inhibitor , Angiotensin II Receptor Blocker , Calcium Channel Blockers , αblockers , Renin Inhibitors , Vasodilators ) 9 . Patients administer medication prohibit concomitant use study period 10 . Patients dependent drug alcohol 11 . Patients surgical medical disease may affect absorption , distribution , metabolism excretion 12 . Patients hypersensitivity component investigational drug . 13 . Patients hypersensitivity Sulfonamide 14 . Patients anuria 15 . Patients hypercalcemia , hyponatremia/hypokalemia 16 . Patients Addison 's disease 17 . Patients hereditary problem galactose intolerance , Lapp lactase deficiency , glucosegalactose malabsorption 18 . Patients chronic accute inflammation disease need chronic inflammation therapy 19 . History malignant tumor include leukemia , lymphoma within 5 year 20 . Patients take clinical trial drug within 30 day time visit screen 21 . Pregnancy , breastfeeding , childbearing potential Patients 22 . Patients judge unsuitable participate study investigator</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>